COMMUNIQUÉS West-GlobeNewswire

Glass House Brands Board of Directors Establishes Product Expansion Committee to Support New Product and Business Development
24/02/2026
LONG BEACH, Calif. and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Apogee Therapeutics to Participate in Upcoming March Conferences
24/02/2026
SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health [...]
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
24/02/2026
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F- [...]
Ocular Therapeutix™ to Participate in March Investor Conferences
24/02/2026
BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the [...]
Full year Trading Update and Notice of Results
24/02/2026
Revenues at the upper end of guidance and pivot to EBITDA profitability - expectations for 2026 unchanged and guidance reiterated Revenues expected to increase c.30% as OXB continues to execute its strategy, FY 2025 [...]
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
24/02/2026
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance [...]
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
24/02/2026
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the [...]
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
24/02/2026
~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non- [...]
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
24/02/2026
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitor NLRP3 inhibitors are a major new class of compounds linked to a broad [...]
EyePoint Announces Participation at Upcoming Investor Conferences
24/02/2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]
Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook
24/02/2026
2025 net revenues increased 5.7% to $1.164 billion , compared to 2024, or 5.2% on a constant currency basis 2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or [...]
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
24/02/2026
Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarter Full year 2025 revenue of $738 million, a year-over-year increase of 16 [...]
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
24/02/2026
Jeito Capital, Novo Holdings and other healthcare investors join Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds Additional capital further supports clinical development of ALV [...]
Indivior to Participate in Upcoming Investor Conferences
24/02/2026
RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global [...]
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
24/02/2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
24/02/2026
Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label study FDA written communications after [...]
Porosome Therapeutics Announces New Porosome-Targeted Medicines Developed Using AI
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the development of novel first-in-class porosome-targeting small molecules and blood brain barrier (BBB) [...]
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
24/02/2026
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release constitutes a “ [...]
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
24/02/2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]

Pages